Clinical Trials Search
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN) Using a Point-Of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork
The purpose of the study is to determine the validity of a point-of-care nerve conduction device (NeuroMetrix) and Rydel-Seiffer tuning fork in assessing the level of peripheral neuropathy in patients with chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy-induced peripheral neuropathy (CIPN) is a common, persistent toxicity among patients who receive chemotherapy. It is characterized by a variety of sensory and motor symptoms such as numbness, tingling, reduced sense of touch, reduced proprioception (awareness of your limb and body position in space), pain, weakness, balance disturbances, and deficits in motor skills.
The primary objectives of this single-arm pilot study is to validate the a point-of-care nerve conduction device ( NeuroMetrix) and Rydel-Seiffer tuning fork as a measurement tool of acupuncture in treatment of patients who suffered from chemotherapy-induced peripheral neuropathy (CIPN). We hypothesize that the inter-operator variability between neurologist and non-neurologist providing measurements independently back-to-back the same day without cross-comparing will have no more than 15% variability